ALL libraries (COBIB.SI union bibliographic/catalogue database)
  • Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors
    Šebeštjen, Miran ...
    The effects of cerivastatin and fenofibrate on proteins involved in haemostasis and on markers of inflammation were investigated in otherwise healthy middle-aged males with combined hyperlipidemia. ... Besides classical riskfactors, other so-called novel risk factors for coronary artery disease are seen to be playing an increasingly important role in the development and progression of atherosclerosis. Thirty-eight males, aged 49 5 years were randomised to 12 weeks treatment either with cerivastatin at a daily dose of 0.2 mg to 0.4 mg to achieve the LDL cholesterol goal of < 3.0 mM, or with fenofibrate 250 mg daily. Fasting serum lipids, homocysteine, total and free tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor (PAI-1) and tissue plasminogen activator (t-PA) antigen and activity, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-alpha) were measured. (Abstract truncated at 2000 characters)
    Source: Thrombosis and haemostasis. - ISSN 0340-6245 (Letn. 92, 2004, str. 1129-1135)
    Type of material - article, component part
    Publish date - 2004
    Language - english
    COBISS.SI-ID - 18764249